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Clinical PerspectiveWhat Is New?There is significant heterogeneity in the cardiac screening process for patients with end‐stage renal disease being evaluated for kidney and/or kidney/pancreas transplant.There is little evidence to suggest that current conservative strategies are effective in mitigating future cardiovascular disease events.What Are the Clinical Implications?We demonstrate that use of an objective metric of cardiorespiratory fitness, such as peak oxygen uptake in the pretransplant cardiovascular screening algorithm, had a high negative predictive value and resulted in minimizing additional cardiac testing.We advocate for the incorporation of cardiorespiratory fitness assessment (peak oxygen uptake) into the pretransplant cardiac screening algorithm.

Introduction {#jah33231-sec-0008}
============

Cardiovascular disease (CVD) is the leading cause of mortality in patients with end‐stage renal disease and in those individuals receiving a kidney transplant. Despite several consensus statements, there is wide variability among centers relating to the cardiac evaluation of a patient before kidney transplant (Tables [S1](#jah33231-sup-0001){ref-type="supplementary-material"} and [S2](#jah33231-sup-0001){ref-type="supplementary-material"}).[1](#jah33231-bib-0001){ref-type="ref"} The variability in practice patterns would indicate that no algorithm is uniformly considered ideal. In addition, none of these algorithms, to our knowledge, include an objective measure of cardiorespiratory fitness.

Peak oxygen uptake (VO~2peak~) is an established objective measure of cardiorespiratory fitness and functional capacity and is a validated predictor of future cardiovascular morbidity and mortality in both healthy and diseased populations. VO~2peak~ \<15 and \<12 mL/kg per minute for men and women with diagnosed coronary heart disease, respectively, has been associated with the highest risk of death.[2](#jah33231-bib-0002){ref-type="ref"} In addition, the measurement of VO~2peak~ is low cost and noninvasive. It outperforms more expensive and invasive tests, such as right‐sided heart catheterization and echocardiogram, as an independent predictor of major adverse cardiovascular events and all‐cause mortality.[2](#jah33231-bib-0002){ref-type="ref"}, [3](#jah33231-bib-0003){ref-type="ref"} VO~2peak~ is the product of maximal cardiac output and maximal arterial‐venous oxygen difference. It represents the ability of the cardiopulmonary system to deliver oxygen to exercising tissue and the ability of peripheral tissues to extract and use oxygen.[4](#jah33231-bib-0004){ref-type="ref"} Individuals experiencing CVD have decreased tissue perfusion, thus necessitating higher tissue oxygen extraction and resulting in decreased VO~2peak~. The typical resting metabolism of a human (resting VO~2~) is 3.5 mL oxygen/kg per minute or by definition 1 metabolic equivalent (MET). Therefore, a 3 MET activity, such as walking at 2.5 mph, expends 3 times the energy used at rest. The MET values of typical activities of daily living have been extensively reported.[5](#jah33231-bib-0005){ref-type="ref"} The measured VO~2peak~ of an individual can be translated to their MET capacity by dividing their VO~2peak~ by 3.5.

The American College of Cardiology/American Heart Association (ACC/AHA) recommends no cardiac testing before intermediate risk surgery, such as a kidney transplant, in an asymptomatic patient with functional status ≥4 METs (ie, VO~2peak~=14 mL/kg per minute), even among those with known cardiac risk factors. However, most US transplant centers do not adhere to the ACC/AHA recommendations and perform, at minimum, a noninvasive cardiac stress test among asymptomatic patients who fit the cardiac high‐risk criteria. The cardiac high‐risk criteria include any of the following: older patients (\>50 years of age), presence of diabetes mellitus, and/or presence of coronary artery disease (CAD). Some centers perform coronary angiography on all cardiac high‐risk patients.

Despite this overcautious and conservative approach, there is little evidence to suggest that these strategies are effective in mitigating future CVD events, but they could potentially introduce more risk and cost with additional testing. None of the current pretransplant cardiac screening strategies objectively quantify and include cardiorespiratory fitness of the patient in the screening algorithm. We hypothesized that incorporating an objective measure of cardiorespiratory fitness, such as VO~2peak~, allows for a safe and cost‐effective pretransplant cardiovascular screening process.

Methods {#jah33231-sec-0009}
=======

Cardiovascular screening for patients undergoing kidney or kidney/pancreas transplant evaluation at Mayo Clinic (Phoenix, AZ) has evolved over time. In October 2011, after extensive discussion with all stake holders, including cardiologists, transplant nephrologists, transplant surgeons, and anesthesiologists, the decision was made to incorporate VO~2peak~, obtained by performing cardiopulmonary exercise test (CPET), into the standard‐of‐care pretransplant cardiac screening algorithm ([Figure](#jah33231-fig-0001){ref-type="fig"}). All patients ≥50 years of age and/or with diabetes mellitus underwent CPET. The VO~2peak~ provided an objective measure of cardiorespiratory fitness and was a branch point metric in the algorithm. Only those with VO~2peak~ \<17 mL/kg per minute underwent further cardiac screening with pharmacologic sestamibi stress test. Among the cohort with known ischemic heart disease with or without prior cardiac intervention, our protocol includes the CPET being performed along with pharmacologic sestamibi stress test, irrespective of the result of VO~2peak~.

![Pretransplant cardiac screening algorithm for kidney and/or pancreas transplant. CABG indicates coronary artery bypass grafting; CAD, coronary artery disease; CPET, cardiopulmonary exercise test; DM, diabetes mellitus; MI, myocardial infarction; TTE, transthoracic echocardiogram; VO ~2peak~, peak oxygen uptake.](JAH3-7-e008662-g001){#jah33231-fig-0001}

Because the ACC/AHA guidelines were not written specifically for patients with end‐stage renal disease with respect to the recommendations of no further cardiac testing among patients with functional capacity of \>4 METs (VO~2peak~=14 mL/kg per minute), we chose to adopt a more conservative measure of VO~2peak~, \<17 mL/kg per minute, to determine if noninvasive stress test should be performed. This is equivalent to an exertion of \>5 METs. This more conservative cutoff for VO~2peak~ at \<17 mL/kg per minute was chosen with the goal of optimizing the negative predictive value (NPV) of the test (ie, to identify those who did not require further testing). Thus, the threshold for VO~2peak~ at \<17 mL/kg per minute was established a priori as a branch point metric in the screening algorithm to rule out the need for further cardiac testing.

Subjects underwent CPET testing on a treadmill/bicycle ergometer using a ramp protocol with the goal of achieving 6 to 9 minutes until voluntary exhaustion occurred. Gas exchange parameters were measured using a computerized breath‐by‐breath analyzer (Medgraphics Corp, St Paul, MN), which was calibrated before each test. A 12‐lead ECG and oxygen saturations were monitored throughout the study, along with periodic blood pressure measurements. The test was conducted by a respiratory technician/exercise specialist, along with a cardiology registered nurse, and interpreted by a cardiologist with specific training in exercise testing.

Study Cohort {#jah33231-sec-0010}
------------

We conducted a retrospective study of all patients with documented VO~2peak~ who were evaluated for kidney/pancreas transplant between November 2011 and September 2014. The study was reviewed and approved by the Institutional Review Board at Mayo Clinic. The informed consent requirement was waived. Patients had an average follow‐up of 4.04±1.11 years after baseline VO~2peak~ testing. During the follow‐up, study outcome events, including CVD event, all‐cause mortality, and a composite outcome of CVD event and all‐cause mortality, were documented. CVD event was defined as cardiac ischemic event, myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, or cerebrovascular accident.

Statistical Analyses {#jah33231-sec-0011}
--------------------

The data, analytic methods, and study materials will not be made available to other researchers because the methods are purely simple statistical methods and transparent and raw data are protected information.

Patient demographic characteristics are displayed comparing those with VO~2peak~ \<17 mL/kg per minute versus those with VO~2peak~ ≥17 mL/kg per minute using Pearson χ^2^ test for categorical variables or 2‐sample *t* test for continuous variables. Log‐rank test was used to compare the outcomes among the 2 groups. The positive predictive value (PPV), NPV, sensitivity, and specificity of VO~2peak~ at end of study period were calculated. Patients with known CAD with VO~2peak~ ≥17 mL/kg per minute were excluded from the analyses calculating PPV and NPV because the algorithm requires a pharmacologic sestamibi stress test in all patients with history of CAD, irrespective of the value of VO~2peak~. *P*\<0.05 was considered statistically significant. All statistical analyses were performed using SAS software, version 9.4 (SAS Institute Inc, Cary, NC).

Results {#jah33231-sec-0012}
=======

Descriptive Analyses of Study Cohort {#jah33231-sec-0013}
------------------------------------

The study cohort included 637 recipients undergoing cardiac evaluation for kidney and/or pancreas transplant. Mean age of study cohort was 56.6 years, 74% were \>50 years of age, 61% were men, 52% were diabetic, and 21% had a history of CAD (9% had cerebrovascular disease and 12% had known peripheral artery disease). During the average follow‐up of 1476.0±408.5 days, 292 individuals received transplant, in which 288 received a kidney transplant. Of the 288 who received a kidney transplant, 71 received living donor transplants and 217 received deceased donor transplants.

Mean VO~2peak~ of study cohort was 15.1±4.4 mL/kg per minute. Among the study cohort of 637 patients receiving CPET, 183 (29%) had a VO~2peak~ ≥17 mL/kg per minute, and 23 of the 183 had history of known CAD. As outlined in the screening algorithm, all patients with CAD had pharmacologic sestamibi stress test performed, irrespective of VO~2peak~; as such, these 23 patients with VO~2peak~ ≥17 mL/kg per minute were excluded from the analyses. Interestingly, among these 23 patients, 16 (70%) had normal pharmacologic sestamibi stress test.

Thus, our study cohort for statistical analyses included a total of 160 patients with VO~2peak~ ≥17 mL/kg per minute who did not undergo further CVD testing, and 454 patients had VO~2peak~ \<17 mL/kg per minute and underwent noninvasive stress test with pharmacologic sestamibi stress test.

Table [1](#jah33231-tbl-0001){ref-type="table"} compares the demographics and baseline characteristics of the patients with VO~2peak~ \<17 versus ≥17 mL/kg per minute. Those with VO~2peak~ \<17 mL/kg per minute were older; were more likely to be women, have history of diabetes mellitus, have history of CVD, and have history of peripheral vascular disease; and were more likely to be past or present smoker and to be taking aspirin.

###### 

Comparison of Demographics and Comorbidities for VO~2peak~ \<17 vs ≥17 mL/kg per Minute

  Variables                          VO~2peak~ \<17 mL/kg per min (N=454)   VO~2peak~ ≥17 mL/kg per min (N=160)   *P* Value
  ---------------------------------- -------------------------------------- ------------------------------------- -----------
  Age, mean (SD), y                  58.3 (11.9)                            51.7 (14.1)                           \<0.0001
  Aged ≥50 y, N (%)                  354 (78)                               98 (61)                               \<0.0001
  Male sex, N (%)                    260 (57)                               110 (69)                              0.011 
  Race, N (%)                                                                                                     0.58
  Black                              52 (11)                                17 (11)                               
  White                              301 (66)                               113 (71)                              
  Others                             101 (22)                               33 (18)                               
  History of comorbidities, N (%)                                                                                 
  Hypertension                       430 (95)                               141 (88)                              0.005
  Diabetes mellitus                  276 (61)                               42 (26)                               \<0.001
  Cerebrovascular disease            45 (10)                                6 (4)                                 0.02
  Peripheral vascular disease        72 (16)                                3 (2)                                 \<0.001
  Hyperlipidemia                     269 (59)                               72 (45)                               0.002
  History of smoking, N (%)                                                                                       0.002
  Never                              218 (48)                               103 (64)                              
  Past                               177 (39)                               42 (26)                               
  Current                            59 (13)                                15 (9)                                
  Pretransplant ASA, N (%)           186 (41)                               49 (27)                               \<0.001
  Type of transplant                                                                                              0.003
  Kidney alone                       182 (40)                               84 (53)                               
  Simultaneous kidney and pancreas   9 (2)                                  3 (2)                                 
  Pancreas alone                     0 (0.0)                                2 (1)                                 

ASA indicates acetylsalicylic acid; VO~2peak~, peak oxygen uptake.

Outcomes: Comparison of Patients With VO~2peak~ \<17 mL/kg per Minute Versus Those With VO~2peak~ ≥17 mL/kg per Minute {#jah33231-sec-0014}
----------------------------------------------------------------------------------------------------------------------

### Cardiovascular events during study period {#jah33231-sec-0015}

A total of 454 patients had VO~2peak~ \<17 mL/kg per minute and underwent pharmacologic sestamibi stress test. As previously described, 160 patients with VO~2peak~ ≥17 mL/kg per minute did not undergo further CVD testing. The PPV and NPV of VO~2peak~ ≥17 mL/kg per minute and future CVD were calculated. We observed a high NPV. We observed this among the entire cohort and subgroups of those who underwent transplant during the follow‐up and those who remained on the wait list (Table [2](#jah33231-tbl-0002){ref-type="table"}).

###### 

Outcomes: Comparing VO~2peak~ \<17 vs ≥17 mL/kg per Minute

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                                                    VO~2peak~ \<17 mL/kg per min (N=Total Number), Event Number   VO~2peak~ ≥17 mL/kg per min (N=Total Number), Event Number   Log‐Rank *P* Value   Sensitivity, %   Specificity, %   Positive Predictive Value, %   Negative Predictive Value, %
  --------------------------------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------ -------------------- ---------------- ---------------- ------------------------------ ------------------------------
  Cardiovascular event (ischemia/CABG/MI/CVA)                                                                                                                                                                                                                                                  

  Entire cohort                                                               (N=454)\                                                      (N=160)\                                                     0.0481               84.9             27.1             9.9                            95.0
                                                                              45                                                            8                                                                                                                                                  

  Wait‐listed cohort                                                          (N=261)\                                                      (N=71)\                                                      0.2341               85.7             22.2             11.5                           93.0
                                                                              30                                                            5                                                                                                                                                  

  Transplanted cohort                                                         (N=193)\                                                      (N=89)\                                                      0.323                81.8             32.1             4.7                            97.8
                                                                              9                                                             2                                                                                                                                                  

  All‐cause mortality                                                                                                                                                                                                                                                                          

  Entire cohort                                                               (N=454)\                                                      (N=160)\                                                     0.0496               79.0             30.2             17.4                           88.5
                                                                              79                                                            17                                                                                                                                                 

  Wait‐listed cohort                                                          (N=261)\                                                      (N=71)\                                                      0.7334               79.7             21.7             24.1                           77.5
                                                                              63                                                            16                                                                                                                                                 

  Transplanted cohort                                                         (N=193)\                                                      (N=89)\                                                      0.0194               94.1             33.2             8.3                            98.9
                                                                              16                                                            1                                                                                                                                                  

  Composite outcome (includes all‐cause mortality and cardiovascular event)                                                                                                                                                                                                                    

  Entire cohort                                                               (N=454)\                                                      (N=160)\                                                     0.0043               84.0             28.8             24.2                           86.9
                                                                              110                                                           30                                                                                                                                                 

  Wait‐listed cohort                                                          (N=261)\                                                      (N=71)\                                                      0.2204               82.7             23.1             31.0                           76.1
                                                                              81                                                            17                                                                                                                                                 

  Transplanted cohort                                                         (N=193)\                                                      (N=89)\                                                      0.0184               88.9             33.7             12.4                           96.6
                                                                              24                                                            3                                                                                                                                                  
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CABG indicates coronary artery bypass grafting; CVA, cerebrovascular accident; MI, myocardial infarction; VO~2peak~, peak oxygen uptake.

Among these 454 patients, with VO~2peak~ \<17 mL/kg per minute, 28 had abnormal pharmacologic sestamibi stress test (presence of ischemia, infarction, and/or ejection fraction \<40) requiring a referral to cardiologist for further recommendations. Cardiac (myocardial infarction, ischemia, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, and/or cerebrovascular accident) events among those patient with VO~2peak~ \<17 versus ≥17 mL/kg per minute were 45 (10%) versus 13 (8%) events (log‐rank *P*=0.23). The detailed description of the 13 events among the patients with VO~2peak~ ≥17 mL/kg per minute is included in Table [S3](#jah33231-sup-0001){ref-type="supplementary-material"}. None of these 13 patients had any significant electrocardiographic changes noted during the CPET test. There was no specific pattern with respect to timing, description of event, and patient characteristics among those with positive event versus those without cardiac event among patients with VO~2peak~ ≥17 mL/kg per minute.

### Mortality during study period {#jah33231-sec-0016}

The PPV and NPV of VO~2peak~ ≥17 mL/kg per minute and all‐cause mortality were calculated. We observed a high NPV. We observed this among the entire cohort and subgroup who underwent transplant during the follow‐up and those who remained on the wait list (Table [2](#jah33231-tbl-0002){ref-type="table"}). Total number of deaths during study period was 100 (15.7%). The death rate among those patients with VO~2peak~ \<17 versus ≥17 mL/kg per minute at the end of study period was 17.4% versus 11.5% (log‐rank *P*=0.074).

Discussion {#jah33231-sec-0017}
==========

Cardiac testing before kidney transplant is highly debated, with no universally adopted pretransplant cardiac screening algorithm. Our proposed algorithm suggests that use of an objective metric of cardiorespiratory fitness, such as VO~2peak~, in the pretransplant cardiovascular screening algorithm had a high NPV and resulted in minimizing additional cardiac testing. In our cohort, ≈25% (160 of 454) of high‐risk patients safely averted further cardiac testing, which resulted in substantial cost savings (≈\$272 600) during the pretransplant cardiac screening.

The literature, including a recent ACC/AHA suggests there is wide variation and heterogeneity in the cardiac screening pretransplant (Tables [S1](#jah33231-sup-0001){ref-type="supplementary-material"} and [S2](#jah33231-sup-0001){ref-type="supplementary-material"}).[1](#jah33231-bib-0001){ref-type="ref"} None of these recommendations use objective measure of cardiorespiratory fitness in the algorithm. The Kidney Disease Outcome Quality Initiative guidelines advocate a more liberal approach in the use of noninvasive stress tests for all high‐risk patients, which is at odds with the ACC/AHA.[1](#jah33231-bib-0001){ref-type="ref"} This could potentially raise concern from insurance companies and payers, questioning adoption of best practices that are not cost‐effective and not congruent with the major cardiac societies\' recommendations with respect to cardiac screening of patients before kidney and/or pancreas transplant. We demonstrated that even in "higher‐risk" patient cohort, the high NPV of VO~2peak~ ≥17 mL/kg per minute supports ACC/AHA guidelines in this group and, thus, prevents unnecessary cardiac testing and results in significant cost savings.

The reimbursement charge of performing the CPET to obtain VO~2peak~ is ≈\$200, and that of pharmacologic sestamibi stress test is \>\$2500. So, in this example, during study time period, 637 "high‐risk" cohorts were evaluated. High risk was defined as anyone with one of the following criteria: ≥50 years of age, presence of diabetes mellitus, and/or history of CAD. All the 637 individuals had the CPET, incurring cost of \$127 400 (\$200×637=\$127 400). A total of 183 (29%) of the study cohort had a VO~2peak~ ≥17 mL/kg per minute; of these individuals, 23 had history of CAD and, thus, had pharmacologic sestamibi stress test, per the protocol. However, 160 patients who otherwise would have had the pharmacologic sestamibi stress test did not have it done \[savings of \$400 000 (160×\$2500)\]. Thus, total cost saving of cardiac screening tests in this example was \$272 600 (\$400 000--\$127 400). Our simple arithmetic calculation alludes to significant cost savings in using this approach; however, a robust formal economic model with cost‐effectiveness analyses will need to be performed to validate the true cost‐effectiveness of this approach.

Cardiorespiratory fitness, as measured by VO~2peak~ as a marker of cardiorespiratory fitness, is a strong predictor of future cardiac events and all‐cause mortality[6](#jah33231-bib-0006){ref-type="ref"} in otherwise healthy individuals and in those with advanced CVD, such as congestive heart failure.[7](#jah33231-bib-0007){ref-type="ref"} The results of this present study are in keeping with the literature that supports the growing body of evidence that cardiorespiratory fitness, as measured by VO~2peak~, can be safely used to rule out future cardiac events and mortality. Thus, VO~2peak~ testing could abrogate the need for more invasive cardiac testing in a cohort of patients with end‐stage renal disease being evaluated for kidney transplant. In addition, event rates in our study were consistent with reported national rates, which enhance the external validity of this study. External validation using our protocol by other transplant programs on their high‐risk phenotype will further consolidate the generalizability of our conclusions.

The goal of cardiac screening and testing before kidney transplant is to identify, intervene, and reduce future cardiovascular morbidity and mortality. The optimal screening test ideally will be cost‐effective, with a high true positive rate and high true negative rate or proportion. However, given the relatively low event rate, a high true PPV may be difficult to achieve. However, one can strive to have high confidence in a negative test. We report a high NPV \>90%, indicating that the high VO~2peak~ (as defined by VO~2peak~ ≥17 mL/kg per minute in this study) among those patients who were able to perform the CPET is sufficient to rule out future cardiac events and all‐cause mortality. However, a low value cannot be used as a reliable predictive measure to determine development of future cardiac events or mortality. We conclude that the current cardiac screening algorithm before kidney and/or pancreas transplant needs to be refined. Incorporation of an objective measure of functional capacity using VO~2peak~ into the pretransplant cardiac screening algorithm is a safe "rule out" test for the requirement of further cardiac testing.
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###### 
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